Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis

Breast

Volumn 22, Issue 5, 2013, Pages 879-886

  Ingoldsby, Helen ^a,b   Webber, Mark ^a   Wall, Deirdre ^a   Scarrott, Carl ^c   Newell, John ^a   Callagy, Grace ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

Breast cancer; Immunohistochemistry; Ki67; Oncotype DX; PR; TAILORx

Indexed keywords

AURORA A KINASE; BAG 1 PROTEIN; CD68 ANTIGEN; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; SURVIVIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AURORA A KINASE GENE; BAG1 GENE; BCL2 GENE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RISK; CD68 GENE; CLASSIFICATION AND REGRESSION TREE ANALYSIS; CYCLIN B1 GENE; DISEASE MARKER; ER GENE; GENE; GENE EXPRESSION REGULATION; GENETIC MARKER; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KI67 GENE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PR GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SURVIVIN GENE;

BREAST CANCER; IMMUNOHISTOCHEMISTRY; KI67; ONCOTYPE DX; PR; TAILORX;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AURORA KINASE A; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL NUCLEUS; CYCLIN B1; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STATISTICS AS TOPIC; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884164688     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.008     Document Type: Article

References (50)

1. Fisher B., Jeong J.H., Bryant J., Anderson S., Dignam J., Fisher E.R., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004, 364:858-868.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
3. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEngl J Med 2004, 351:2817-2826. Epub 004 Dec 10.
4. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. JClin Oncol 2006, 24:3726-3734. Epub 2006 May 23.
5. Sparano J.A. The TAILORx trial: individualized options for treatment. Community Oncol 2006, 3:3.
6. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 25:5287-5312. Epub 2007 Oct 22.
7. NCCN guidelines 2012, Accessed at:. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
8. Kelly C.M., Krishnamurthy S., Bianchini G., Litton J.K., Gonzalez-Angulo A.M., Hortobagyi G.N., et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010, 116:5161-5167. 10.1002/cncr.25269.
9. Allison K.H., Kandalaft P.L., Sitlani C.M., Dintzis S.M., Gown A.M. Routine pathologic parameters can predict Oncotype DX(TM) recurrence scores in subsets of ER positive patients: who does not always need testing?. Breast Cancer Res Treat 2011, 3:3.
10. Flanagan M.B., Dabbs D.J., Brufsky A.M., Beriwal S., Bhargava R. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008, 21:1255-1261.
11. Geradts J., Bean S.M., Bentley R.C., Barry W.T. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010, 28:969-977.
12. Auerbach J., Kim M., Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?. Arch Pathol Lab Med 2010, 134:1697-1701.
13. Cuzick J., Dowsett M., Pineda S., Wale C., Salter J., Quinn E., et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. JClin Oncol 2011, 29:4273-4278. Epub 2011 Oct 11.
14. Leake R., Barnes D., Pinder S., Ellis I., Anderson L., Anderson T., et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. JClin Pathol 2000, 53:634-635.
15. Therneau T.M., Atkinson B. rpart: Recursive partitioning. R package version 3.1-46. Rport 2011, B. Ripley (Ed.).
16. Hothorn T., Hornik K., Zeileis A. Unbiased recursive partitioning: a conditional inference framework. JComput Graph Stat 2006, 15.
17. Liaw A., Wiener M. Classification and regression by randomForest. RNews 2002, 18-22.
18. Breiman L., Friedman J., Stone C.J., Olsen R.A. Classification and regression trees 1984, Chapman and Hall/CRC. New ed.
19. Strobl C, Malley J, Tutz G. Supplement to an introduction to recursive partitioning: rationale, application and characteristics of classification and regression trees, bagging and random forests. 2009.
20. Baehner F.L., Maddala T., Alexander C., Gown A., Goldstein L.C., Achacoso N.S., et al. AKaiser-Permanente population-based study of ER and PR expression by the standard method, immunohistochemistry (IHC), compared to a new method, quantitative reverse transcription polymerase chain reaction (RT-PCR). ASCO breast cancer symposium 2007, San Francisco, L.A.
21. Gwin K., Pinto M., Tavassoli F.A. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score. Int J Surg Pathol 2009, 17:303-310. Epub 2009 Jul 3.
22. Tang P., Wang J., Hicks D.G., Wang X., Schiffhauer L., McMahon L., et al. Alower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest 2010, 28:978-982.
23. Liu S., Chia S.K., Mehl E., Leung S., Rajput A., Cheang M.C., et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010, 119:53-61. Epub 2009 Feb 10.
24. Stendahl M., Ryden L., Nordenskjold B., Jonsson P.E., Landberg G., Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006, 12:4614-4618.
25. Arpino G., Weiss H., Lee A.V., Schiff R., De Placido S., Osborne C.K., et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. JNatl Cancer Inst 2005, 97:1254-1261.
26. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
27. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
28. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNatl Cancer Inst 2009, 101:736-750. Epub 2009 May 12.
29. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Leung S., Nielsen T., et al. AKi67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. JPathol 2012, 226:97-107. Epub 011 Sep 26. 10.1002/path.2976.
30. Luporsi E., Andre F., Spyratos F., Martin P.M., Jacquemier J., Penault-Llorca F., et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012, 132:895-915. Epub 2011 Nov 3.
31. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. JNatl Cancer Inst 2011, 103:1656-1664. Epub 2011 Sep 29.
32. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747. Epub 2011 Jun 27.
33. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. Epub 2009 Jun 17.
34. Romero Q., Bendahl P.O., Klintman M., Loman N., Ingvar C., Ryden L., et al. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer 2011, 11:341.
35. Keshgegian A.A., Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 1995, 104:42-49.
36. Bevilacqua P., Verderio P., Barbareschi M., Bonoldi E., Boracchi P., Dalla Palma P., et al. Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat 1996, 37:123-133.
37. Aleskandarany M.A., Rakha E.A., Macmillan R.D., Powe D.G., Ellis I.O., Green A.R. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 2010, 11:11.
38. Clahsen P.C., van de Velde C.J., Duval C., Pallud C., Mandard A.M., Delobelle-Deroide A., et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 1999, 25:356-363.
39. Joensuu H., Isola J., Lundin M., Salminen T., Holli K., Kataja V., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9:923-930.
40. Goodson W.H., Moore D.H., Ljung B.M., Chew K., Mayall B., Smith H.S., et al. The prognostic value of proliferation indices: a study with invivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat 2000, 59:113-123.
41. Viale G., Regan M.M., Mastropasqua M.G., Maffini F., Majorano E., Colleoni M., et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. JNatl Cancer Inst 2008, 100:207-212. Epub 2008 Jan 29.
42. Blanc-Brude O.P., Mesri M., Wall N.R., Plescia J., Dohi T., Altieri D.C. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003, 9:2683-2692.
43. Rexhepaj E., Jirstrom K., O'Connor D.P., O'Brien S.L., Landberg G., Duffy M.J., et al. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer 2010, 10:639.
44. Kuhling H., Alm P., Olsson H., Ferno M., Baldetorp B., Parwaresch P., et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. JPathol 2003, 199:424-431.
45. Rudolph P., Kuhling H., Alm P., Ferno M., Baldetorp B., Olsson H., et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003, 105:674-680.
46. Suzuki T., Urano T., Miki Y., Moriya T., Akahira J., Ishida T., et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 2007, 98:644-651. Epub 2007 Mar 14.
47. Aaltonen K., Amini R.M., Heikkila P., Aittomaki K., Tamminen A., Nevanlinna H., et al. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer 2009, 100:1055-1060. Epub 2009 Mar 17.
48. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Pharoah P.D., Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer 2012, 26:167.
49. Wolf I., Ben-Baruch N., Shapira-Frommer R., Rizel S., Goldberg H., Yaal-Hahoshen N., et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008, 112:731-736.
50. Ademuyiwa F.O., Thorat M.A., Jain R.K., Nakshatri H., Badve S. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol 2010, 23:270-275. Epub 2009 Nov 27.